bismuth has been researched along with rabeprazole in 19 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (21.05) | 29.6817 |
2010's | 9 (47.37) | 24.3611 |
2020's | 6 (31.58) | 2.80 |
Authors | Studies |
---|---|
Ohkusa, T; Sato, N | 1 |
Abudayyeh, S; Belson, G; Dore, MP; El-Zimaity, HM; Graham, DY; Osato, MS | 1 |
Mahachai, V; Thong-Ngam, D | 1 |
Cheng, H; Hu, FL | 1 |
Cheng, H; Gao, W; Hu, F; Zhang, X; Zhang, Y | 1 |
Aktaş, B; Başyiğit, S; Kefeli, A; Nazlıgül, Y; Uzman, M; Yeniova, AÖ | 1 |
Bair, MJ; Hsu, PI; Hsu, WH; Hu, CT; Hu, HM; Jheng, GH; Kuo, CH; Kuo, FC; Liu, CJ; Shih, HY; Wu, DC; Wu, IC; Wu, MC | 1 |
Aslan, M; Basyigit, S; Kefeli, A; Kefeli, TT; Tanas, O; Yeniova, AO | 1 |
Song, Z; Suo, B; Zhang, L; Zhou, L | 1 |
Robotis, J; Rokkas, T; Tsiodras, S | 1 |
Chen, S; Liu, D; Lu, H; Lv, N; Wang, J; Xie, Y; Zeng, Z; Zhang, L; Zhang, Z; Zhu, Z | 1 |
Azmi, AN; Goh, KL; Graham, DY; Leow, AH; Loke, MF; Vadivelu, J | 1 |
Chen, Y; Gu, L; He, Y; Jiang, Y; Li, S; Liu, X; Peng, Y; Yang, H | 1 |
Hu, F; Liu, Y; Teng, G; Wang, H; Wang, W; Wu, T | 1 |
Ding, SZ; Hu, RB; Jia, BL; Lan, L; Ma, J; Qi, YB; Shao, QQ; Wei, PR; Xiao, W; Yu, M; Yu, XC; Yuan, L; Zhang, LZ; Zhao, JB | 1 |
Hsu, PI; Kao, J; Lin, MH; Shie, CB; Tsay, FW; Wang, JW; Wu, DC; Wu, IT | 1 |
Abbondio, M; Bibbò, S; Dore, MP; Loria, M; Niolu, C; Pes, GM; Sau, R; Tanca, A; Uzzau, S | 1 |
Chen, S; Dong, Q; Liu, Y; Shen, W; Shi, Y | 1 |
Du, Q; Li, Y; Liao, O; Liu, X; Lou, G; Wang, Y; Wu, H; Wu, Y; Ye, J | 1 |
1 review(s) available for bismuth and rabeprazole
Article | Year |
---|---|
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline | 2002 |
11 trial(s) available for bismuth and rabeprazole
Article | Year |
---|---|
Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Pilot Projects; Prospective Studies; Proton-Translocating ATPases; Rabeprazole; Salicylates; Tetracycline; Treatment Outcome | 2004 |
Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole; Treatment Outcome; Young Adult | 2009 |
Different treatment choice for first-line treatment of Helicobacter pylori in an area with a high antibiotic resistance.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Turkey | 2014 |
Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rabeprazole; Tetracycline | 2015 |
Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; Cross-Over Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Potassium Citrate; Prospective Studies; Rabeprazole; Tetracycline; Time Factors; Young Adult | 2016 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Protein Synthesis Inhibitors; Proton Pump Inhibitors; Rabeprazole; Tetracycline; Young Adult | 2018 |
Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Young Adult | 2018 |
Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Rabeprazole; Treatment Outcome | 2022 |
Metagenomic Changes of Gut Microbiota following Treatment of
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Limosilactobacillus reuteri; Metronidazole; Proton Pump Inhibitors; Rabeprazole; RNA, Ribosomal, 16S; Tetracycline; Treatment Outcome | 2022 |
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Berberine; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2023 |
Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; China; Clarithromycin; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Rabeprazole; Randomized Controlled Trials as Topic; Single-Blind Method | 2023 |
7 other study(ies) available for bismuth and rabeprazole
Article | Year |
---|---|
14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Ranitidine; Tetracycline; Treatment Failure | 2006 |
Tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for Helicobacter pylori infection: a single center retrospective study.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole; Retrospective Studies; Tetracycline; Treatment Outcome; Young Adult | 2014 |
Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Helicobacter Infections; Humans; Male; Medication Adherence; Middle Aged; Minocycline; Prospective Studies; Rabeprazole; Treatment Outcome | 2016 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell; Metronidazole; Middle Aged; Organometallic Compounds; Rabeprazole; Salicylates | 2018 |
Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Rabeprazole; Young Adult | 2019 |
Efficacy of Sucralfate-Combined Quadruple Therapy on Gastric Mucosal Injury Induced by
Topics: Amoxicillin; Animals; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Mice; Proton Pump Inhibitors; Rabeprazole; Sucralfate | 2020 |
The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Proton Pump Inhibitors; Rabeprazole; Tetracycline; Treatment Outcome | 2022 |